Company intelligence / Profile preview
Violet Therapeutics
Cambridge, Massachusetts, United Statesviolettx.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Violet Therapeutics has developed proprietary platforms to map the cellular connectome at scale. Their lead program targets neuroinflammation in multiple neurodegenerative indications, with a particular focus on Alzheimer’s disease. The company remains pre-clinical as of 2023 and has raised significant seed funding to advance its programs
- Therapeutic areas
- OncologyImmunologyNeurology
- Modalities
- First-in-class drug discovery platforms
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Dementia Discovery Fund (DDF)UTEC/University of Tokyo Edge Capital PartnersMass General Brigham VenturesOno Venture Investment
Beyond the preview
Go deeper on Violet Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Violet Therapeutics.